In our analysis, we evaluated changes in the levels of biochemical markers—CA-125 and HE4—and the expression profile of genes and proteins encoded by them associated with drug resistance in patients with ovarian cancer in comparison to control subjects. The gene discussed is WFDC2; the disease is ovarian carcinoma.